ANT-GROUP
20.9.2022 02:25:47 CEST | Business Wire | Press release
Nike today announced that it has joined Ant Group’s Green Energy Initiative and launched an official mini program on Alipay, the leading digital open platform, to encourage more consumers to recycle worn-out shoes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005601/en/
Students play basketball on Nike Grind court (Photo: Business Wire)
Chinese consumers can search the mini program “Recycle-A-Shoe” in the Alipay app and have worn-out Nike shoes collected for recycling. The shoes will then be dismantled and re-processed to make sustainable sport courts through Nike Grind technology. By doing so, consumers will receive virtual green energy points in Alipay Ant Forest, a green mini program. These green energy points can be used to support tree planting, ecological restoration or bio-diversity conservation projects.
“In China, Nike continues to strive toward its goal of ‘Move to Zero’ and encourages the public to take part in environmental protection. The innovative cooperation with Ant Group allows Nike’s Recycle-A-Shoe program to reach more consumers through digital solutions on the Alipay platform and incorporates Nike’s sustainability efforts into daily life, which is our long-term commitment,” said Stanley Chang, Vice President of Operations and Logistics of Nike Greater China.
“In the face of increasing challenges brought on by climate change, the private sector needs to encourage more environmental-friendly actions among consumers while committing themselves to reducing carbon emission in their business operations. We are delighted to partner with Nike to promote low carbon actions and better protect the environment through innovative solutions in recycling,” said Cheng Jiang, General Manager of Social Good Department, Ant Group.
Nike’s global “Recycle-A-Shoe” program has been active for 30 years. More than 30 million pairs of worn-out shoes and over 120 million pounds of footwear factory materials have been recycled and transformed into innovative sports products, such as basketball courts, soccer fields, running tracks, yoga equipment and interior decoration.
Launched in 2016, Alipay Ant Forest is a green initiative that encourages users to adopt low carbon activities in their daily life, which has attracted over 650 million participants since its inception. Users can gain green energy points for low carbon actions, including biking to work instead of driving and paying electricity bills online instead of offline.
Ant Group’s Green Energy Initiative, which features green energy points in Alipay Ant Forest, is open to brands that would like to offer their customers more incentives to take green actions. As of August 2022, the initiative has attracted participation from more than 500 brands across multiple sectors including travel, packaging and home appliance manufacturing.
About Move to Zero
In its commitment to the long-term plan of sustainable development, Nike launched "Move to Zero" in 2019 with the aim of operating with zero carbon emissions and zero waste. This initiative has been implemented across all aspects of design, manufacturing and transportation. Significant progress has also been made in Nike moving closer to its ambitious goal of “Move to Zero”. In September (2022), Nike announced the launch of the CLC Wind Runner Project in the China Logistics Center. After its completion and implementation in early 2023, the Nike China Logistics Center will be operating with 100% renewable energy. In regard to sustainable product innovation, Nike has launched a subversively innovative platform - Nike Forward, which will bring great changes to the apparel industry.
About Alipay
In the evolving digital era, Alipay has transformed from a payment tool of public trust to an open platform for businesses, institutions, service providers, and other partners. Business partners in various industries utilize Alipay to offer consumers a safe and convenient payment experience. Through digital operation, business partners can communicate and provide various commercial and daily life digital services for their clients via Alipay mini programs, lifestyle accounts, and IoT, along with other tools available. Currently, there have been over 80 million businesses serving more than 1 billion consumers via Alipay’s open platform services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005601/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
